Analyzing our results based on the results of other research teams that the JAK inhibition has the therapeutic effect of multiple myeloma, we are expected that radotinib will play an important role in the treatment of multiple myeloma as the radotinib has an excellent effect on STAT3 and JAK2 inhibition. The gene discussed is JAK2; the disease is plasma cell myeloma.